Steven Leonard Chapman Sells 78,553 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the transaction, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. The trade was a 22.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, November 15th, Steven Leonard Chapman sold 4,728 shares of Natera stock. The shares were sold at an average price of $146.41, for a total value of $692,226.48.
• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $468,111.60.

Natera Stock Down 0.1 %

Shares of NTRA opened at $171.82 on Friday. Natera, Inc. has a 52 week low of $62.96 and a 52 week high of $183.00. The stock has a market capitalization of $22.68 billion, a price-to-earnings ratio of -97.63 and a beta of 1.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a fifty day moving average of $165.35 and a 200-day moving average of $135.41.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.95) EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Chartwell Investment Partners LLC raised its position in Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the last quarter. Cerity Partners LLC raised its position in Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Natera during the 3rd quarter worth $385,000. Everence Capital Management Inc. acquired a new stake in Natera during the 4th quarter worth about $573,000. Finally, First Turn Management LLC acquired a new stake in Natera during the 3rd quarter worth about $19,760,000. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. The Goldman Sachs Group upped their target price on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Canaccord Genuity Group increased their price target on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Piper Sandler increased their price target on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Leerink Partners increased their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Craig Hallum increased their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $162.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.